OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(2)
2023
(2)
2024
(1)
2022
(1)
2021
(1)
2020
(1)
2018
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
Not available
S-EPMC6886126
|
biostudies-literature
Cite
Population-specific polygenic risk scores for people of Han Chinese ancestry.
Not available
S-EPMC12675292
|
biostudies-literature
Cite
The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies.
Not available
S-EPMC12675286
|
biostudies-literature
Cite
Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
Not available
S-EPMC10658267
|
biostudies-literature
Cite
Low-Density Lipoprotein Cholesterol and Mortality in Patients With Intracerebral Hemorrhage in Taiwan.
Not available
S-EPMC8802633
|
biostudies-literature
Cite
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry.
Not available
S-EPMC10518516
|
biostudies-literature
Cite
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Not available
S-EPMC9054878
|
biostudies-literature
Cite
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Not available
S-EPMC10830583
|
biostudies-literature
Cite
Robust estimation of bacterial cell count from optical density.
Not available
S-EPMC7499192
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets